Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed ...

The MCU is split into Phases, with the end of a Phase typically indicating a natural ... Prices start at $9.99 / £4.99 / AU$15.99 per month (or $99.99 / £89.90 / AU$159.99 per year).

With a 4-tap pixel structure, we achieved motion artifact-free depth map. Peak current during exposure time has been reduced by current spreading with constant delay chain in the photo-gate driver.

One-year EFS rates were 51.4% (95% CI, 41.0 to 64.3), 43.1% (95% CI, 31.3 to 59.5), and 38.7% (95% CI, 24.1 to 62.0) in arm 1, arm 2, and control arm, respectively. Conclusion The feasibility and ...

The Climate Strategy, approved by Council on July 5, 2022, guides Calgary toward two main goals. These are progressing towards net-zero greenhouse gas (GHG) emissions by 2050 and becoming a more ...

asDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden ...